Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial
Published on March 17, 2026.
Pfizer's experimental drug, Atmosatirmociclib, was being tested in a mid-stage study in patients whose cancer had spread and had received prior treatment. The study enrolled patients who returned soon after treatment, a group that is difficult to treat. Over 90% of patients started using the drug within three months of stopping their previous cancer medicine. The results support plans to test atmosaticlib in first-line and early-stage of breast cancer, where longer-lasting disease control could help more patients.
Related Articles
XRP-associated Ripple seeking VASP license in Brazil
Ripple is expanding its digital asset services in Brazil, seeking a VASP license from the country’s central bank, as part of broader operations.
Key MAHA Initiative Can Save Consumers, Businesses 26x The Money, Report Shows
Adopting a national food labeling standard could save American businesses 26x the cost of complying with 50 state-specific mandates, despite potential price increases.
Josh Pyatt Joins Patrick Whitesell’s WTSL as Firm Gets Into Management With WIN Artists (Exclusive)
WTSL, led by Patrick Whitesell, is entering management with Josh Pyatt leading WIN Artists, a division focusing on diversifying sports stars and businesses.